Holen Sie sich die Stockscreener-App
15.90
4.10%
-0.68
Schlusskurs vom Vortag:
$16.58
Offen:
$16.55
24-Stunden-Volumen:
1.27M
Relative Volume:
0.92
Marktkapitalisierung:
$956.65M
Einnahmen:
$439.00K
Nettoeinkommen (Verlust:
$-105.64M
KGV:
-8.8333
EPS:
-1.8
Netto-Cashflow:
$-60.70M
1W Leistung:
+0.25%
1M Leistung:
-39.95%
6M Leistung:
-38.70%
1J Leistung:
-74.21%
1-Tages-Spanne:
$15.86
$16.77
1-Wochen-Bereich:
$15.51
$17.37
52-Wochen-Spanne:
$15.51
$66.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Vergleichen Sie JANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
15.90 | 997.25M | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Eingeleitet | Stifel | Buy |
| 2025-09-10 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-11 | Eingeleitet | Raymond James | Outperform |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-12-03 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-03-21 | Eingeleitet | BTIG Research | Buy |
| 2024-03-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 - AOL.com
Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test? - Yahoo Finance
Optimistic Buy Rating for Janux Therapeutics Despite Challenges and Promising Market Potential - TipRanks
Janux Therapeutics (JANX): Valuation Check After Positive JANX007 Phase 1 Data and Sharp Share Price Drop - Yahoo Finance
Andrew Hollman Meyer Sells 3,333 Shares of Janux Therapeutics (NASDAQ:JANX) Stock - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Janux Therapeutics' (JANX) Outperform Rating Reaffirmed at Wedbush - MarketBeat
What analysts say about Janux Therapeutics Inc stockFundamental Strength Indicators & High Return Investment Plans - earlytimes.in
Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound - Stocktwits
Janux Therapeutics Sees Unusually Large Options Volume (NASDAQ:JANX) - MarketBeat
Analysts Unfazed By Janux’s Weaker Prostate Cancer Results - Citeline News & Insights
12/2/2025 Market UpdateWinners: XHLD, TLRY, HPPLosers: SONN, JANX, ABTCS&P 500: 0% - Trefis
Janux Therapeutics (NASDAQ:JANX) Sets New 1-Year Low After Analyst Downgrade - MarketBeat
Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data - Seeking Alpha
Bank of America Issues Pessimistic Forecast for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Janux tanks despite claiming positive trial results for JANX007 in mCRPC - The Pharma Letter
Janux Therapeutics (NASDAQ:JANX) Given New $150.00 Price Target at Cantor Fitzgerald - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Pfizer (PFE) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Merck & Company (MRK), Alibaba Health Information Technology (OtherALBHF) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy - geneonline.com
Janux shares halve despite still strong Phase I data - BioCentury
Janux stock falls as UBS maintains Buy rating despite disappointing data By Investing.com - Investing.com South Africa
Clear Street Maintains Janux Therapeutics (JANX) Buy Recommendation - Nasdaq
Stifel Maintains Janux Therapeutics (JANX) Buy Recommendation - Nasdaq
Janux Therapeutics stock price target lowered to $45 by H.C. Wainwright - Investing.com South Africa
Janux Therapeutics stock price target lowered to $150 by Cantor Fitzgerald - Investing.com Nigeria
Truist Securities reiterates Buy rating on Janux Therapeutics stock By Investing.com - Investing.com South Africa
Apple, Boeing, MongoDB, Credo, Warner Bros. Discovery, Janux, Ford, Marvell, and More Movers - Barron's
Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'? - Investor's Business Daily
Biotech Trio Gets Hammered On Heavy Trading - Finimize
Stock Movers: Boeing, Janux Therapeutics, Signet - Bloomberg.com
Boeing, MongoDB, Credo, Warner Bros. Discovery, Janux, Ford, Marvell, and More Movers - Barron's
Investors flee Janux after updated prostate cancer results disappoint - FirstWord Pharma
Janux Therapeutics stock hits 52-week low at 18.34 USD By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Janux T-cell engager data sink stock, but analysts still see best-in-class potential - Fierce Biotech
Janux dives as gaps in prostate cancer study data worry investors - MSN
Janux Therapeutics Stock Hits 52-Week Low After Trial Update - Benzinga
Janux sinks on ‘overreaction’ to prostate cancer data; RFK Jr. replaces ACIP chair - BioPharma Dive
Janux stock falls as UBS maintains Buy rating despite disappointing data - Investing.com Nigeria
Janux Therapeutics (JANX) Stock: Why Did Shares Crash 41% on "Positive" News? - parameter.io
Applovin, MongoDB among market cap stock movers on Tuesday By Investing.com - Investing.com South Africa
Applovin, MongoDB among market cap stock movers on Tuesday - Investing.com
Truist Securities reiterates Buy rating on Janux Therapeutics stock - Investing.com
Boeing, MongoDB, Credo, Warner Bros. Discovery, Janux, Marvell, and More Movers - Barron's
Biggest stock movers Tuesday: CRDO, MDB, BA, and more - Seeking Alpha
Janux lets the genie out of the bottle | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Janux Therapeutics Stock Craters After ‘Positive’ Cancer Data. Why It’s Down 50%. - Barron's
Nasdaq Surges 200 Points; United Natural Foods Posts Upbeat Earnings - Benzinga
Applied Materials To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):